Sector News

MSD buys UK cancer drug discovery group IOmet

January 13, 2016
Life sciences

MSD has snapped up British drug discovery group IOmet, securing access to a new batch of preclinical cancer candidates to help stock up its early R&D pipeline.

The move sees Edinburgh, UK-based IOmet – which is focused on the development of innovative oncology medicines with a particular emphasis on cancer immunotherapy and metabolism – become a wholly-owned subsidiary of MSD (called Merck in the US).

The deal, financial terms of which were kept under wraps, adds a comprehensive preclinical pipeline of IDO (indoleamine-2,3-dioxygenase 1), TDO (tryptophan-2,3-dioxygenase), and dual-acting IDO/TDO inhibitors to MSD’s pipeline.

IDO1 and TDO are key targets in the cancer immunotherapy field, as over-expression of these enzymes has been detected in a variety of cancers – including glioma, melanoma, lung, ovarian, and colorectal cancers – and is associated with poor prognosis and survival.

“Extensive preclinical evidence, and emerging clinical data, suggests that inhibition of IDO1 and/or TDO may synergise with, and help overcome resistance to, existing clinical cancer therapies, in particular other immunotherapy-based treatments,” said MSD.

According to Eric Rubin, vice president and therapeutic area head, oncology early-stage development, at Merck Research Laboratories, “the acquisition of IOmet is a further example of Merck’s commitment to fully realising the potential of this rapidly evolving field through our existing innovative portfolio as well as the acquisition of promising immunotherapeutic candidates”.

By Selina McKee

Source: Pharma Times

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.